Gene · 23521
NIH grants2,185
NIH grants whose papers are about the gene, through NIH's grant-paper links.
441 to 460 of 2,185
Download this page as JSON| Grant | Title | RPL13A papers | Newest fiscal year |
|---|---|---|---|
| P50CA098131 | SPORE in Breast Cancer | 1 | 2024 |
| R00AG065419 | Lifestyle intervention to treat apathy in older adults | 1 | 2024 |
| R00MH119327 | The role of autism susceptibility genes in the 16p11.2 locus on the development and function of human stem cell-derived neural cells | 1 | 2024 |
| R01AI055258 | Synthetic Ligands for Directing Immune Responses | 1 | 2024 |
| R01AI108682 | How beta-catenin expands Foxp3+RORgammat+ Pro-inflammatoryT-regulatory cells - Renewal | 1 | 2024 |
| R01AI114362 | Transcriptional regulatory mechanisms shaping HIV proviral fate | 1 | 2024 |
| R01AI118426 | Molecular Basis of Human Toxoplasmosis | 1 | 2024 |
| R01AI141486 | Galectins in Modulating Immune Responsiveness of IgE-bearing Cells | 1 | 2024 |
| R01AI150986 | Evolution and consequences of multidrug resistant ribosome | 1 | 2024 |
| R01AI151051 | Biophysical and functional characterization of immune-related regulatory elements and noncoding variants | 1 | 2024 |
| R01AI155577 | Temporal control of differentiation and epigenetics of Exhausted CD8 T cells by Tox | 1 | 2024 |
| R01AI157155 | Human antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2 | 1 | 2024 |
| R01CA138804 | Role of PALB2 in the DNA Damage Response and Cancer Suppression | 1 | 2024 |
| R01CA193318 | Damaged RNA as a mediator of alkylation responses | 1 | 2024 |
| R01CA238237 | Understanding and Overcoming Resistance to BRAF/MEK Kinase Inhibitors in Melanoma | 1 | 2024 |
| R01CA238662 | Targeting the Circadian Rhythm in Glioblastoma Stem Cells (R01CA238662) | 1 | 2024 |
| R01CA242020 | Targeting an RNA Binding Protein Network in Acute Myeloid Leukemia | 1 | 2024 |
| R01CA243547 | Impact of mutation burden on cancer growth and the immune landscape | 1 | 2024 |
| R01CA246304 | Integrated analysis of HCC CTCs for Liver Transplant Candidate Selection | 1 | 2024 |
| R01CA253651 | HCC EV Digital Scoring Assay for assessing treatment response in HCC patients | 1 | 2024 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/23521/grants?page=23